Backing Eli Lilly (LLY) over C

Backing Eli Lilly (LLY) over CVNA and LHX for the coming quarter. While Carvana relies heavily on fragile retail volume recovery and L3Harris faces defense execution friction, LLY’s thesis is anchored in structural, inelastic demand for GLP-1 therapeutics.

The strategy is simple: accumulate post-earnings pullbacks toward key moving averages rather than chasing initial valuation spikes. The driver isn't multiple expansion—it's raw execution on volume conversion and global capacity expansion.
My Invalidation Trigger: A sustained deceleration in weekly prescription (TRx/NRx) growth trends combined with net realization price erosion. If yield compresses faster than volume scales, margin compression will cap the next leg up regardless of top-line hype.

Ticker & Trigger: LLY — Buying pullbacks at the 20-day SMA, invalidated if TRx growth drops below 2% QoQ. Margin resilience remains the non-negotiable metric.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":624237924913328,"tweetId":"624237924913328","gmtCreate":1793435383153,"gmtModify":1793435387124,"author":{"id":3572753591805453,"idStr":"3572753591805453","authorId":3572753591805453,"authorIdStr":"3572753591805453","name":"zhingle","avatar":"https://static.tigerbbs.com/c02cf1400ebf75fbfd40821cde407263","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/0641f4c5fa60c48f6d3ce6febffedc88","smallImgUrl":"https://community-static.tradeup.com/news/1e30711ea2bab5f411df0be106fc0244","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.10.17","individualDisplayEnabled":1,"backgroundColor":{"dark":"#2f2a1f","tint":"#fcf6e5"},"fontColor":{"dark":"#dea95e","tint":"#885600"}}],"wearingBadges":[{"categoryType":2007,"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","smallImgUrl":"https://community-static.tradeup.com/news/1e30711ea2bab5f411df0be106fc0244","bigImgUrl":"https://community-static.tradeup.com/news/0641f4c5fa60c48f6d3ce6febffedc88","isScarce":1,"plateColors":{"bgColor":{"dark":"#2f2a1f","tint":"#fcf6e5"},"fontColor":{"dark":"#dea95e","tint":"#885600"}},"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","redirectLinkValidityFrom":1679961600000,"redirectLinkValidityTo":1996963200000,"validityToTimestamp":1794759601636,"sortingWeight":0,"wearable":1}],"fanSize":62,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body>Backing Eli Lilly (LLY) over CVNA and LHX for the coming quarter. While Carvana relies heavily on fragile retail volume recovery and L3Harris faces defense execution friction, LLY’s thesis is anchored in structural, inelastic demand for GLP-1 therapeutics. \n \n \n \nThe strategy is simple: accumulate post-earnings pullbacks toward key moving averages rather than chasing initial valuation spikes. The driver isn't multiple expansion—it's raw execution on volume conversion and global capacity expansion. \n \nMy Invalidation Trigger: A sustained deceleration in weekly prescription (TRx/NRx) growth trends combined with net realization price erosion. If yield compresses faster than volume scales, margin compression will cap the next leg up regardless of top-line hype. \n \n \n \nTicker &amp; Trigger: LLY — Buying pullbacks at the 20-day SMA, invalidated if TRx growth drops below 2% QoQ. Margin resilience remains the non-negotiable metric.</body></html>","htmlText":"<html><head></head><body>Backing Eli Lilly (LLY) over CVNA and LHX for the coming quarter. While Carvana relies heavily on fragile retail volume recovery and L3Harris faces defense execution friction, LLY’s thesis is anchored in structural, inelastic demand for GLP-1 therapeutics. \n \n \n \nThe strategy is simple: accumulate post-earnings pullbacks toward key moving averages rather than chasing initial valuation spikes. The driver isn't multiple expansion—it's raw execution on volume conversion and global capacity expansion. \n \nMy Invalidation Trigger: A sustained deceleration in weekly prescription (TRx/NRx) growth trends combined with net realization price erosion. If yield compresses faster than volume scales, margin compression will cap the next leg up regardless of top-line hype. \n \n \n \nTicker &amp; Trigger: LLY — Buying pullbacks at the 20-day SMA, invalidated if TRx growth drops below 2% QoQ. Margin resilience remains the non-negotiable metric.</body></html>","text":"Backing Eli Lilly (LLY) over CVNA and LHX for the coming quarter. While Carvana relies heavily on fragile retail volume recovery and L3Harris faces defense execution friction, LLY’s thesis is anchored in structural, inelastic demand for GLP-1 therapeutics. The strategy is simple: accumulate post-earnings pullbacks toward key moving averages rather than chasing initial valuation spikes. The driver isn't multiple expansion—it's raw execution on volume conversion and global capacity expansion. My Invalidation Trigger: A sustained deceleration in weekly prescription (TRx/NRx) growth trends combined with net realization price erosion. If yield compresses faster than volume scales, margin compression will cap the next leg up regardless of top-line hype. Ticker & Trigger: LLY — Buying pullbacks at the 20-day SMA, invalidated if TRx growth drops below 2% QoQ. Margin resilience remains the non-negotiable metric.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/624237924913328","repostId":0,"isVote":1,"tweetType":1,"viewCount":418,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":786,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/624237924913328"}